TY - JOUR
T1 - Efficacy of a nurse-led sexual rehabilitation intervention for women with gynaecological cancers receiving radiotherapy
T2 - results of a randomised trial
AU - Suvaal, Isabelle
AU - Hummel, Susanna B.
AU - Mens, Jan Willem M.
AU - Tuijnman-Raasveld, Charlotte C.
AU - Tsonaka, Roula
AU - Velema, Laura A.
AU - Westerveld, Henrike
AU - Cnossen, Jeltsje S.
AU - Snyers, An
AU - Jürgenliemk-Schulz, Ina M.
AU - Lutgens, Ludy C.H.W.
AU - Beukema, Jannet C.
AU - Haverkort, Marie A.D.
AU - Nowee, Marlies E.
AU - Nout, Remi A.
AU - de Kroon, Cor D.
AU - van den Hout, Wilbert B.
AU - Creutzberg, Carien L.
AU - van Doorn, Helena C.
AU - ter Kuile, Moniek M.
N1 - Funding Information:
The SPARC trial was supported by a grant from the Dutch Cancer Society/ Alpe d\u2019HuZes fund (grant 10674). The funding body had no role in study design, data collection, data interpretation, data analysis or writing of this report.
Funding Information:
The SPARC study was supported by a grant from the Dutch Cancer Society, Alpe d\u2019HuZes fund (grant number 10674). We thank the patients and their families who participated in this trial and contributed their time and efforts to complete the many questionnaires. We are indebted to the oncology nurses, brachytherapy technicians, radiotherapy medical assistants, supervisors, and multidisciplinary clinical research teams at the participating centres. We express our gratitude to the independent panel for their efforts in assessing the adherence to the treatment protocol, as well as evaluating the competency of the trained nurses. The patient advocacy group for gynaecological cancers Olijf provided information at their website and provided input before and during the course of the study []. This study was presented in part at the International Psycho-Oncology Society World Congress (Milan, Italy, August 31\u2013September 3 2023).
Publisher Copyright:
© The Author(s) 2024.
PY - 2024/9/21
Y1 - 2024/9/21
N2 - Background: The multicentre randomised SPARC trial evaluated the efficacy of a nurse-led sexual rehabilitation intervention on sexual functioning, distress, dilator use, and vaginal symptoms after radiotherapy for gynaecological cancers. Methods: Eligible women were randomised to the rehabilitation intervention or care-as-usual. Four intervention sessions were scheduled over 12 months, with concurrent validated questionnaires and clinical assessments. Primary outcome was the Female Sexual Function Index (FSFI). A generalised-mixed-effects model compared groups over time. Results: In total, 229 women were included (n = 112 intervention; n = 117 care-as-usual). No differences in FSFI total scores were found between groups at any timepoint (P = 0.37), with 12-month scores of 22.57 (intervention) versus 21.76 (care-as-usual). The intervention did not significantly improve dilator use, reduce sexual distress or vaginal symptoms compared to care-as-usual. At 12 months, both groups had minimal physician-reported vaginal stenosis; 70% of women were sexually active and reported no or mild vaginal symptoms. After radiotherapy and brachytherapy, 85% (intervention) versus 75% (care-as-usual) of participants reported dilation twice weekly. Discussion: Sexual rehabilitation for women treated with combined (chemo)radiotherapy and brachytherapy improved before and during the SPARC trial, which likely contributed to comparable study groups. Best practice involves a sexual rehabilitation appointment 1 month post-radiotherapy, including patient information, with dilator guidance, preferably by a trained nurse, and follow-up during the first year after treatment. Clinical trial registration: NCT03611517.
AB - Background: The multicentre randomised SPARC trial evaluated the efficacy of a nurse-led sexual rehabilitation intervention on sexual functioning, distress, dilator use, and vaginal symptoms after radiotherapy for gynaecological cancers. Methods: Eligible women were randomised to the rehabilitation intervention or care-as-usual. Four intervention sessions were scheduled over 12 months, with concurrent validated questionnaires and clinical assessments. Primary outcome was the Female Sexual Function Index (FSFI). A generalised-mixed-effects model compared groups over time. Results: In total, 229 women were included (n = 112 intervention; n = 117 care-as-usual). No differences in FSFI total scores were found between groups at any timepoint (P = 0.37), with 12-month scores of 22.57 (intervention) versus 21.76 (care-as-usual). The intervention did not significantly improve dilator use, reduce sexual distress or vaginal symptoms compared to care-as-usual. At 12 months, both groups had minimal physician-reported vaginal stenosis; 70% of women were sexually active and reported no or mild vaginal symptoms. After radiotherapy and brachytherapy, 85% (intervention) versus 75% (care-as-usual) of participants reported dilation twice weekly. Discussion: Sexual rehabilitation for women treated with combined (chemo)radiotherapy and brachytherapy improved before and during the SPARC trial, which likely contributed to comparable study groups. Best practice involves a sexual rehabilitation appointment 1 month post-radiotherapy, including patient information, with dilator guidance, preferably by a trained nurse, and follow-up during the first year after treatment. Clinical trial registration: NCT03611517.
U2 - 10.1038/s41416-024-02775-8
DO - 10.1038/s41416-024-02775-8
M3 - Article
SN - 0007-0920
VL - 131
SP - 808
EP - 819
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 5
ER -